Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
171. |
ECCT/21/03/02 | PB-SAM Pancreatic Enzymes and Bile Acids: A Non-Antibiotic approach to Treat Intestinal Dysbiosis in Acutely Ill Severely Malnourished Children. |
Principal Investigator(s) 1. Robert Bandsma Site(s) in Kenya 1. Kilifi County Hospital (Kilifi county) 2. Coast General Hospital (Mombasa county) 3. Mbagathi Hospital (Nairobi City county) 4. Migori County Hospital (Migori county) |
08-06-2021 |
View |
172. |
ECCT/20/12/03 | CALINA STUDY A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria. Study number: CCOA566B2307 |
Principal Investigator(s) 1. Benhards Ragama Ogutu Site(s) in Kenya KEMRI-Centre for Clinical Research (CCR) |
08-03-2021 |
View |
173. |
ECCT/21/02/01 | PTSD 102 TONIX A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P308). |
Principal Investigator(s) 1. Prof. Lukoye Atwoli Site(s) in Kenya 1. Moi Teaching and Referral Hospital/Moi University (Uasin Gishu county) 2. KEMRI Nairobi (Nairobi City county) 3. Aga Khan University Hospital (Nairobi City county) |
16-06-2021 |
View |
174. |
ECCT/20/10/04 | yellow fever vaccine CVIA 079 A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079. |
Principal Investigator(s) 1. Dr. Deborah Langat Site(s) in Kenya KEMRI/KERICHO CLINIC RESEARCH CENTRE |
28-12-2020 |
View |
175. |
ECCT/20/09/02 | BEe-HIVe B-ENHANCEMENT OF HBV VACCINATIONIN PERSONS LIVING WITH HIV (BEe-HIVe) EVALUATION OF HEPLISAV-B,A5379 |
Principal Investigator(s) 1. JOSPHAT KOSGEI Site(s) in Kenya KEMRI/KERICHO CLINIC RESEARCH CENTRE |
27-11-2020 |
View |
176. |
ECCT/20/10/02 | MALCOV Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso (MALCOV) |
Principal Investigator(s) 1. Simon Kariuki 2. Helen Barsosio Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOORTH), (Kisumu county) 2. Kisumu County Referral Hospital. (Kisumu county) 3. Alupe sub-County Hospital, (Busia county) 4. Bondo sub-County Hospital, (Siaya county) 5. Macalder (Nyatike) sub-County Hospital (Migori county) 6. Migori County Teaching and Referral Hospital; (Migori county) |
23-11-2020 |
View |
177. |
ECCT/20/08/02 | ALIVE study Evaluation of the effectiveness of IVERMECTIN co-formulation vs ALBENDAZOLE for treatment of for the Treatment of Soil-Transmitted Helminth Infections (Trichuris trichiura, hookworm, Strongyloides stercoralis) in school aged children and Young Adult Subjects (ALIVE Study) |
Principal Investigator(s) 1. Charles Mwandawiro Site(s) in Kenya Kwale |
12-01-2021 |
View |
178. |
ECCT/20/06/04 | ANTICOV (01 COV) An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19 |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. Mbagathi Infectious Disease Hospital (Nairobi City county) 2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county) |
18-09-2020 |
View |
179. |
ECCT/20/06/02 | EMPACTA Covid19 Study A RANDOMIZED, DOUBLE-BLIND, Placebo-Controlled, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID‑19 PNEUMONIA |
Principal Investigator(s) 1. Reena Shah Site(s) in Kenya AgaKhan University Hospital Nairobi |
09-07-2020 |
View |
180. |
ECCT/20/07/03 | STAND A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND) |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. CREATES Strathmore University (Nairobi City county) 2. Getrudes Childrens Hospital (Nairobi City county) 3. International Cancer Institute (Elgeyo/Marakwet county) |
30-11-2020 |
View |